Kezar Life Sciences (NASDAQ:KZR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Thursday.

According to Zacks, “Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company’s product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California. “

Several other research firms have also weighed in on KZR. Cowen initiated coverage on shares of Kezar Life Sciences in a report on Monday, July 16th. They set an “outperform” rating on the stock. Wells Fargo & Co initiated coverage on shares of Kezar Life Sciences in a report on Monday, July 16th. They set an “outperform” rating and a $30.00 target price on the stock. William Blair initiated coverage on shares of Kezar Life Sciences in a report on Monday, July 16th. They set an “outperform” rating on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Kezar Life Sciences in a report on Monday, July 16th. They set a “buy” rating and a $23.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Kezar Life Sciences has a consensus rating of “Buy” and an average price target of $26.50.

NASDAQ:KZR opened at $24.58 on Thursday. Kezar Life Sciences has a twelve month low of $14.77 and a twelve month high of $26.86.

Kezar Life Sciences (NASDAQ:KZR) last posted its earnings results on Thursday, November 8th. The company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.18. Research analysts forecast that Kezar Life Sciences will post -2.64 earnings per share for the current year.

Hedge funds have recently modified their holdings of the business. Frazier Management LLC acquired a new position in Kezar Life Sciences in the 2nd quarter worth $4,325,000. Prosight Management LP acquired a new position in Kezar Life Sciences in the 2nd quarter worth $721,000. FMR LLC acquired a new position in Kezar Life Sciences in the 2nd quarter worth $25,995,000. Cowen Inc. acquired a new position in Kezar Life Sciences in the 2nd quarter worth $18,207,000. Finally, Dean Capital Investments Management LLC acquired a new position in Kezar Life Sciences in the 2nd quarter worth $585,000. Hedge funds and other institutional investors own 42.19% of the company’s stock.

About Kezar Life Sciences

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

See Also: What is a conference call?

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.